Loading...
Loading...
- GlaxoSmithKline Plc's GSK turnover was £9.07 billion in Q3, up 5% Y/Y (actual exchange rate AER), 10% (constant exchange rate CER).
- Pharmaceuticals sales reached £4.4 billion, up 5% AER, 10% CER. Sales of Xevudy, the COVID-19 monoclonal antibody treatment, and contributed approximately 3 percentage points to total Pharmaceuticals growth.
- COVID-19 solutions sales £209 million including Xevudy £114 million and pandemic adjuvant £94 million.
- Vaccines sales grew 7% AER, 13% CER to £2.2 billion, primarily driven by higher Shingrix sales in the U.S. and Europe and pandemic adjuvant sales.
- Vaccines turnover excluding pandemic vaccines grew 2% AER, 8% CER to £2.2 billion.
- Adjusted operating margin of 31.7% is 0.8 percentage points higher at AER and 1.5 percentage points higher on a CER basis than Q3 2020.
- Adjusted EPS was 36.6p, up 3% AER, 10% CER.
- The net cash flow from operations was £2.6 billion. The free cash outflow was £1.2 billion.
- Outlook: GlaxoSmithKline expects the 2021 adjusted EPS outlook to decline between 2% to 4% at CER, against a previously mid-to-high single-digit decline.
- GSK reconfirms a meaningful improvement in revenues and margins in 2022.
- Price Action: GSK shares are up 0.31% at $40.31 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in